Antimicrobial resistance (AMR) has been identified by the World Health
Organization (WHO) as a serious global health threat. Already, an estimated
33 000 patients die each year in the EU from infections caused by drug
resistant bacteria and this results in estimated economic losses of around
€1.5 billion annually due to extra health care costs and productivity losses.
The World Bank has warned that, by 2050, drug-resistant infections could
cause as much global economic damage as the 2008 financial crisis.
The European Court of Auditors is conducting an audit on the Commission’s
and relevant agencies’ management of key activities and resources to support
Member States as well as EU research aimed at fighting AMR. In particular,
we are focusing on the support provided by Commission and the European
Centre for Disease Prevention (ECDC) to Member States on strengthening
their One Health Action Plans, on the EU framework for monitoring
antimicrobial resistance and consumption in the veterinary sector, and on the
Commission’s and agencies’ coordination, targeting and evaluation
mechanisms within the framework of EU support for AMR research.
If you wish to contact the audit team, you may do so at the following email